Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer CAMBRIDGE, Mass., Dec. 21, 2020 — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine to drive systemic effects, today announced the appointment of Jonathan Zung, Ph.D., as Chief Development Officer and a member of the Evelo Executive Team. Dr. Zung is an established industry veteran,...